Eli Lilly’s COVID-19 antibody treatment, Bamlanivimab, is being distributed across the country. More than 2,750 vials of the drug are expected to arrive in the Hoosier state by mid November.
Earlier this month the FDA gave emergency use authorization for the treatment. The U.S. government has purchased 300,000 doses to go to high-risk patients. The antibody treatment is for mild to moderate COVID-19 cases in adults and patients 12 years or older.
The goal is to reduce hospitalizations. The drug was made in Indianapolis and is the first of its kind.